4//SEC Filing
Zarrabian Saiid 4
Accession 0000899243-21-047320
CIK 0001498382other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 4:09 PM ET
Size
12.0 KB
Accession
0000899243-21-047320
Insider Transaction Report
Form 4
Zarrabian Saiid
DirectorInterim CEO
Transactions
- Purchase
Common Stock
2021-12-07$0.64/sh+38,109$24,298→ 55,500 total - Purchase
Common Stock
2021-12-06$0.59/sh+11,891$7,018→ 17,391 total
Holdings
- 590(indirect: By Children)
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.5902 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
- [F2]On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63115 to $0.6415 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Issuer
Kintara Therapeutics, Inc.
CIK 0001498382
Entity typeother
Related Parties
1- filerCIK 0001495521
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 4:09 PM ET
- Size
- 12.0 KB